Free Newsletter
New ethics standards could derail stem cell projects
Top stem cell scientists say that the NIH's newly-outlined ethical standards threaten to derail a variety of stem cell research projects currently underway.
"We're very concerned," Amy Comstock Rick, chief executive of the Coalition for the Advancement of Medical Research, tells the Washington Post. "If they don't change this, very little current research would be eligible. It's a huge issue."
Stem cell advocates say research work currently underway lived up to the ethical standards in practice earlier, but may well not pass muster under the stricter guidelines pushed by the Obama administration as it loosened federal funding restrictions on the field.
"We'd have to throw everything out and start all over again," said Lawrence S. Goldstein, director of the stem cell program at the University of California at San Diego.
- read the report from the Washington Post
Related Articles:
New administration adds billions more for R&D
NIH budgets $24M to jump-start programs
Stimulus to double cancer research grants
Stimulus money spurs biomedical research work
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: